Puerarin suppresses hypoxia-induced vascular endothelial growth factor upregulation in human retinal pigmented epithelial cells by blocking JAK2/STAT3 pathway

Huixin Tang, Lingchun Kong, Yuqin Yang, Jingjing Li, and Hong Zou

Department of Ophthalmology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai China

ABSTRACT
The purpose of this study was to explore the mechanism by which puerarin regulated the expression of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) in humans’ retinal pigment epithelial (RPE) cells under hypoxia. RPE cells (ARPE-19 and D407 cells) and a rat model of oxygen-induced retinopathy were used in the current study. Western blotting and ELISA were performed to detect the level of JAK2, phosphorylated JAK2, STAT3, phosphorylated STAT3, HIF-1α, and VEGF in cells. In addition, the interaction between JAK2 and STAT3 was determined using with a co-immunoprecipitation assay. We found puerarin inhibited hypoxia-induced upregulation of VEGF at both the mRNA and protein level via decreasing HIF-1α expression in RPE cells. Moreover, puerarin attenuated the interaction between JAK2 and STAT3, and subsequently blocking p-STAT3 nucleus translocation in vitro and in vivo. In conclusion, puerarin could effectively inhibit hypoxia-induced VEGF upregulation in RPE cells via mediated JAK2/STAT3 pathway.
Highlights

- Puerarin inhibited hypoxia-induced upregulation of VEGF at both the mRNA and 34 protein levels in RPE cells
- Puerarin decreased HIF1α expression in RPE cells under hypoxia.
- Puerarin attenuated the interaction between JAK2 and STAT3, and subsequently 37 blocking p-STAT3 nucleus translocation.

Introduction

Wet age-related macular degeneration (AMD) is the leading cause of blindness in people over 60 and the main feature of AMD is choroidal neovascularization (CNV) [1]. Recent studies have shown that tissue hypoxia caused by retinal vascular disease in the elderly plays a vital role in CNV progression [2]. Therefore, elucidating the molecular mechanism underlying hypoxia-induced neovascularization is of great significance for the treatment of AMD.

As we know, retinal pigment epithelial (RPE) cells are able to induce the generation of new blood vessels via secreting vascular endothelial growth factor (VEGF) under hypoxia [3]. However, the neovascularization is accompanied by retinal tissue damage due to the formation of fibrous tissue, and ultimately resulting in vision loss [4]. In addition, it has been demonstrated that the level of VEGF in the vitreous membrane of patient with AMD was significantly increased, and neutralization of VEGF in the retina can effectively inhibit the formation of new blood vessels [5–7]. Thus, VEGF-blocking therapy has become an effective method for the treatment of AMD. For example, pegaptanib (a 28-base RNA aptamer targeting VEGF) and bevacizumab (a humanized VEGF monoclonal antibody) significantly alleviate the progression of AMD by inhibiting the activity of VEGF in the retina tissues [8,9]. Nevertheless, all these molecules require high-dose and repeated administration. Meanwhile, the systemic side effects greatly limit their application [10,11]. Therefore, exploring of new drugs that can effectively inhibit retinal neovascularization is greatly important for the patients with AMD.

As a heterodimeric complex composed of a stable hypoxic subunit (HIF-1α) and a stable nuclear subunit (HIF-1β); the activation of transcriptional regulator hypoxia-inducible factor (HIF) plays a vital key role during the process of neovascularization [12].

Puerarin isolated from the traditional Chinese herb Radix Pueraria lobata [13], has been long used as an anti-diuretic, anti-pyretic and diaphoretic medicine [14,15]. Previous studies reported that puerarin could be used to treat various diseases including cardio-cerebrovascular disease and neurodegenerative disorders [16,17]. In a recent study, expression of pigment epithelium-derived growth factor in bladder cancer cells was significantly inhibited by puerarin treatment; that means puerarin was able to inhibit the neovascularization in tumor tissues [18]. Therefore, puerarin might play a role in regulating the progression of choroidal neovascularization. In the present study, we aimed to explore the effect of puerarin on the progression of AMD.

Method and material

A rat model of oxygen-induced retinopathy

All animal procedures were performed in accordance with the statements of the University of Utah and the University of North Carolina (Guidelines for the Care and Use of Laboratory Animals) and the Vision and Ophthalmology Research Association. Oxygen-induced retinopathy (OIR) lesions in a newborn Sprague-Dawley rat was established as previously described [19]. Briefly, entire litters of newborn rat pups and dams were provided with Charles River (Beijing, China). Then, newborn rats were put into a controlled oxygen environment for 14 days. The oxygen concentration of this environment cycled between 50% and 10% every 24 h. Puerarin was dissolved with normal saline; the rats were intraperitoneally injected with 100 mg/kg puerarin once a day for 14 days.

Retinal tissue collection

Rats were anesthetized by intraperitoneal injection of ketamine (20 mg/kg)/xylazine (6 mg/kg). Then, the rats were sacrificed and the retinas were removed and flat-mounted under microscope using with glycerol gelatin [19].
Cell culture and hypoxic treatment

Human RPE cells (ARPE-19 and D407 cells) were purchased from the Bacterial Collection Center of Wuhan University. These cells were cultured in a DMEM medium (Thermo Fisher) that was supplemented with 1% non-essential amino acids, 29 mM sodium bicarbonate, 10% FBS, 20 mM HEPES, 100 μg/ml streptomycin and 100 U/ml penicillin (Sigma Aldrich) [20]. Cells were cultured at 37°C, 5% CO2 humidity condition. For hypoxic treatment, cells were placed in the incubator with 1% O2, 5% CO2, 94% N2 for 3, 6, or 12 h. Puerarin was purchased from Solarbio and BXL0124 (STAT3 inhibitor) was provided with BioXell, Inc. These two agents were added into the culture medium for 12 h before hypoxia treatment.

Cell viability detection

Human RPE cells (ARPE-19 and D407 cells) were treated with different concentration of puerarin (5, 10, 20 or 40 μM) for 12 h, and the cell viability was detected with CCK8 kit (Beyotime) following the manufacturer’s protocol.

RNA isolation and reverse-transcriptase polymerase chain reaction (RT-qPCR)

Cell and tissue RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer’s protocol [21]. For each sample, 1 μg total RNA, 5.0 μM oligo-d(T), and Reverse transcriptase kit (Takara Bio, Inc., Otsu, Japan) were used for single-strand cDNA synthesis. Then, RT-qPCR analysis was performed using an RT-qPCR kit (Takara Bio, Inc.) following the manufacturer’s protocol. PCR amplification procedure was 95°C for 5 min pre-denaturation, followed by 35 cycles of 95°C for 15 sec denaturation and 62°C for 20 sec elongations. The primer sequence of HIF-1α: forward, 5’-GAAAAC CACCTATGACCTGC-3’ and reverse, 5’-CTGT TTGTTGAAGGGAGAA-3’; the primer sequence of VEGF: forward, 5’- CTTTGGCTGCTCTACCTCC-3’ and reverse, 5’-AAATGCTTTCTCCGCTCT-3’; the primer sequence of α-tubulin: forward, 5’-CGGG CAGTGTGTGTAGACTTGG-3’ and reverse, 5’-TCCTTGCAATGGGTAGTG-3’. α-tubulin was used as an internal control.

Protein extraction and western blot

Total protein of cell and retinal samples were extracted with modified RIPA buffer (120 mmol/L NaCl, 0.5% sodium deoxycholate, 20 mmol/L Tris base, 0.1% SDS, 10% glycerol, 1% Triton X-100 and 1 mmol/L orthovanadate) that supplemented with protease cocktail inhibitor (1:100; Sigma-Aldrich). The supernatant protein was quantified using BCA Protein Assay (Pierce). Then, each sample (10 μg protein) was separated with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane (Millipore). The membranes were then blocked with 5% fat-free milk for 1 h at room temperature and incubated against specific primary antibodies overnight at 4°C, following incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Finally, the signals were visualized by using the ECL chemiluminescence kit (Pierce) [22].

For co-immunoprecipitation (Co-IP), cells were lysed in IP lysis buffer (Pierce) and then centrifuged at 15,000 x g for 10 min at 4°C. The supernatant was collected and incubated against the indicated primary antibody overnight at 4°C. Further, protein G Sepharose beads (GE) were added and incubated at 4°C for 4 h; the beads were boiled in 100 μL 2× SDS loading buffer for 10 min and the supernatant was used for western blot. The primary antibodies are as follows: Phosphorylated-JAK2 (p-JAK2), JAK2 (1:1000; Abcam), phosphorylated-STAT3 (p-STAT3), STAT3 (1:1000; Cell Signaling Technology), HIF-1α (1:500; Santa Cruz Biotechnology) and VEGF (1:1000; Abcam).

Retinal tissue staining

Retinas tissue in 10 μm section were firstly incubated in proteinase K (10 μg/mL) for 15 minutes and treated with 5% goat serum for another 2 min. Then, the section of retina was blocked with 10% normal goat serum for 1 h at room temperature. After that, sections were incubated with primary antibody anti-phosphorylated STAT3 (p-STAT3; Y705; 1:50; Cell Signaling
Technology) and Fluorescein-dextran (1:100, Sigma Aldrich) overnight at 4°C [23]. Finally, the sections were incubated with Alexa 488-conjugated rabbit secondary antibody (1:1000, Invitrogen) for 1 h and mounted in Fluoromount-G (Southern Biotech). Images were obtained with an inverted microscope (Olympus).

**ELISA**

The level of HIF-1α and VEGF in the supernatant of the culture medium was determined using with HIF-1α and VEGF ELISA kits (R&D) accordingly to the manufacturer’s instructions [23].

**Cell transfections**

RPE cells were transfected with STAT3 pcDNA3.1 plasmid (0.5 μg/μl; General Bio) using Lipofectamine 2000 reagent (Life Technologies) for 24 h in order to overexpress STAT3 (STAT3 OE) [24]. As for HIF-1α knockdown, cells were transfected with HIF-1α siRNA (10 nM) for 24 h using Lipofectamine 2000 reagent. The sequence of HIF-1α siRNA: sense, 5’-CAGAAAUGGCCUUGUGAAA-3’; antisense, 5’-UUUCACAAGGCAUUUUCUG-3’.

**Fluorescence microscopy**

Cells were firstly fixed and incubated with the p-STAT3 (1:100; Abcam) or CD31 (1:100; Abcam) antibody (Cell Signaling Technology, 1:500) overnight at 4°C, as previously described. After being washed three times, these cells were sequentially incubated with Fluorophore-conjugated secondary antibody (Alexa Fluor 488 or 546; Invitrogen, 1:200) at room temperature for 60 min. Cell nuclear was stained with DAPI nuclear antibody (Invitrogen, 1 mM) at room temperature for 15 min. The fluorescence was captured using a confocal microscope (Olympus) [25].

![Figure 1. Puerarin reverses hypoxia-induced VEGF upregulation in RPE cells.](image-url)

(a, b) RPE (ARPE-19 and D407) cells exposure to hypoxia for 3, 6 or 12 h, the mRNA level of HIF-1α and VEGF was examined by RT-qPCR. (c) RPE cells were pre-treated with puerarin (5, 10, 20 μM) for 12 h and exposure to hypoxia for 12 h. VEGF mRNA level in cells were detected with RT-qPCR. (d) VEGF level in the culture medium of RPE cells was detected with ELISA. *P < 0.05, **P < 0.01 compared with normoxia; ##P < 0.01 compared with hypoxia; n = 3.
Statistical Analyses

Each experiment was performed at least three times, and the results are expressed as mean ± S. D. One-way ANOVA with post-hoc Tukey test was used to determine the significant difference among multiple groups (>2 groups). P < 0.05 was considered a significant difference [20].

Results

Puerarin reverses hypoxia-induced VEGF upregulation in RPE cells

We firstly explore the effect of puerarin on VEGF expression in RPE cells under hypoxia. RPE cells (ARPE-19 and D407 cells) were exposed to normoxia or hypoxia for 3, 6, or 12 h. And the mRNAs level of HIF-1α and VEGF were determined with RT-qPCR. As indicated in Figure 1a and 1b, hypoxia time-dependently upregulated the expression of HIF-1α and VEGF in RPE cells. In addition, hypoxia-induced VEGF upregulation in both cell lines was remarkably reversed by puerarin treatment (Figure 1c). Inconsistent with the RT-qPCR data, puerarin markedly reduced the VEGF content in the medium compared with hypoxia group (Figure 1d). Moreover, puerarin dose-dependently inhibited the proliferation of RPE cells (Supplementary Fig. 1). Thus, 5 μM puerarin was selected of used in the following experiments. These data suggested puerarin was able to inhibit hypoxia-induced VEGF upregulation in RPE cells.

Puerarin represses JAK2/STAT3 signaling in RPE cells under hypoxia

Since HIF-1α and VEGF expression was tightly regulated by JAK2/STAT3 signaling [26], we next explored the effect of puerarin on JAK2/STAT3 pathway in RPE cells under hypoxia. As shown in Figure 2a and 2b, hypoxia treatment significantly upregulated the protein level of p-JAK2, p-STAT3 and HIF-1α in a time-dependent manner; however, these phenomena were significantly reversed by puerarin. Meanwhile, hypoxia-induced upregulation of p-JAK2, p-STAT3 and HIF-1α in cells was completely inhibited by STAT3 inhibitor (Figure 2a and 2b).

To further determine STAT3 activity in cells, p-STAT3 was analyzed immunofluorescence staining. The result of staining suggested intense p-STAT3 was observed in ARPE-19 and D407 cells under hypoxia; however, p-STAT3 immunofluorescence staining was significantly reduced by puerarin treatment (Supplementary Fig. 2). All these data indicated that puerarin might inhibit

![Figure 2. Puerarin represses JAK2/STAT3 signaling in RPE cells under hypoxia. (a, b) RPE cells were pre-treated with puerarin (10 μM) or BioXell for 12 h. Then, cells were incubated under hypoxia for 6 or 12 h. Western blotting was performed to detect the expression of p-STAT3, STAT3, HIF-1α, p-JAK2 and JAK2 in cells. (b) Cells pretreated with 10 μM puerarin following 6 or 12 h hypoxic incubation. **P < 0.01; n = 3.](image-url)
HIF-1α and VEGF expression of RPE cells under hypoxia by blocking JAK2/STAT3 pathway.


Puerarin inhibits the interaction between JAK2 and STAT3 in RPE cells under hypoxia

Under the condition of hypoxia, JAK2 was phosphorylated and leading to the phosphorylation of STAT3 [27]. Then, STAT3 trans-located into cell nuclear and activated the downstream target genes such as HIF-1α and VEGF [28]. In this study, the result of co-IP showed that puerarin notably attenuated interaction between JAK2 and STAT3 (Figure 3a). To further verify the biological relationship between these factors, western blot was performed. The outcome of western blot indicated hypoxia-induced p-STAT3, HIF-1α and VEGF upregulation was completely reversed by puerarin; however, the effects of puerarin on these proteins were abolished by STAT3 OE (Figure 3b and 3c). All these data illustrated puerarin prevented hypoxia-induced HIF-1α and VEGF upregulation in RPE cells by inhibiting JAK2/STAT3 signaling.

Puerarin inhibits retinal neovascularization in a rat model of OIR

With the purpose of investigating the effect of puerarin on retinal neovascularization, a rat model of OIR was established. As indicated in fluorescein angiography analysis (fluorescein-dextran staining), OIR significantly induced retinal neovascularization; however, this phenomenon was reversed by puerarin treatment (Figure 4a). Additionally, OIR notably increased the expression of HIF-1α and VEGF in retinal tissues; whereas OIR-induced upregulation of HIF-1α and VEGF was inhibited by puerarin treatment as well (Figure 4b and 4c). Taken together, puerarin inhibited OIR-induced neovascularization might
via downregulation of HIF-1α and VEGF expression in retinal tissues.

**Puerarin inhibits STAT3 nuclear translocation in a rat model of OIR**

In order to evaluate the effect of puerarin on STAT3 activity in vivo, p-STAT3 level in retinal tissue was evaluated with western blot and immunofluorescence staining. As shown in Figure 5a, the level of p-STAT3 was notably increased in OIR group; however, OIR-induced p-STAT3 upregulation was completely reversed by puerarin treatment. Inconsistent with the result of western blot, the p-STAT3 level in the retina was profoundly elevated by OIR treatment compared with the control group, while puerarin administration inhibited p-STAT3 level in these tissues (Figure 5b). In addition, vascular marker CD31 was significantly increased in OIR group, whereas this phenomenon was reversed by puerarin treatment (Figure 5b). All these data indicated that puerarin was able to inhibit STAT3 nuclear translocation in a rat model of OIR.

**Discussion**

Puerarin is a multifunctional molecule, which has been shown to exhibit anti-tumor and anti-inflammatory effects [29,30]. In a previous study, puerarin has been demonstrated to inhibit VEGF expression and the formation of blood vessels [31]. Therefore, we speculated puerarin may inhibit the progression of CNV by downregulating the expression of VEGF. In this study, we demonstrated that 12 h of hypoxia exposure could increase the expression level of HIF-1α and VEGF in RPE cells, which is consistent with previous reports [32–35]. As expected, hypoxia-induced VEGF upregulation in RPE cells was significantly inhibited by puerarin treatment. Moreover, puerarin was found to notably inhibit the expression of HIF-1α in RPE cells under hypoxia. It is well known that hypoxia can lead to the activation of HIF-1α, which in turn results in VEGF upregulation [36]. In addition, hypoxia stimulates RPE cells to release VEGF, thereby promoting the progression of CNV [37]. Thus, we deduced puerarin regulated the expression of VEGF in RPE cells under hypoxia may via mediating HIF-1α level.

The JAK2/STAT3 pathway has previously been found to be involved in hypoxia-induced upregulation of VEGF and HIF-1α in RPE cells [38,39]. Upon stimulation, JAK2 is activated by phosphorylation and interact with STAT3, thus leading to the phosphorylation of STAT3; p-STAT3 subsequently trans-locates to the
nucleus and activates its downstream target genes including HIF-1α and VEGF [40]. In the present study, we found puerarin significantly inhibited the level of p-JAK2 and p-STAT3 of RPE cells under hypoxia. More important, over-expression of STAT3 abolished the effect of puerarin on HIF-1α and VEGF expression in RPE cells. All these results indicated that puerarin regulated HIF-1α and VEGF expression via mediating JAK2/STAT3 pathway. It should be noted that puerarin didn’t affect HIF-1α and VEGF expression in RPE cells under normoxia, which is a great advantage for its usage.

However, the detailed mechanism by which puerarin regulated the interaction between JAK2 and STAT3 remain unclear and more investigations are needed in future.

**Conclusion**

The present study demonstrated that puerarin effectively inhibited hypoxia-induced VEGF upregulation in RPE cells via mediated JAK2/STAT3 pathway. Therefore, puerarin might serve as a potential agent for the treatment of patient with AMD.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was financially supported by the National Key R&D Program of China (81874384); National Natural Science Foundation of China (81874384).
Author contribution

HZ conceived and designed the project, YY, LK and HT acquired the data, LK and JL analysed and interpreted the data, HZ wrote the paper.

Ethical Statement

All animal procedures were approved by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine animal welfare committee.

References

[1] Lai TY, Cheung CM. MYOPIC CHOROIDAL NEOVASCULARIZATION: diagnosis and treatment. Retina. 2016;36:1614–1621.
[2] Campochiaro PA, Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog Retin Eye Res. 2021;83:100921.
[3] Kurihara T, Westenskow PD, Gantner ML, et al. Hypoxia-induced metabolic stress in retinal pigment epithelial cells is sufficient to induce photoreceptor degeneration. eLife. 2016;5. DOI:10.7554/eLife.14319.
[4] Datta S, Cano M, Erbaimi K, et al. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017;60:201–218.
[5] Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22.
[6] Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:697–707.
[7] Li Y, Busoy JM, Zaman BAA, et al. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies. Exp Eye Res. 2018;174:98–106.
[8] Edington M, Connolly J, Chong NV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol. 2017;13:1217–1224.
[9] Tah V, Orlans HO, Hyer J, et al. Anti-VEGF therapy and the retina: an Update. J Ophthalmol. 2015;2015:627674.
[10] Fogli S, Del Re M, Rofi E, et al. Clinical pharmacology of intravitreal anti-VEGF drugs. 2018;32:1010–1020.
[11] Sánchez Ramón A, Piñón Mosquera R, Mendieta Rasos N. Response to anti-VEGF therapy in macular oedema secondary to acute retinal necrosis. Arch Soc Esp Oftalmol. 2019;94:41–44.
[12] Peet DJ, Kittipassorn T, Wood JP, et al. HIF signalling: the eyes have it. Exp Cell Res. 2017;356:136–140.
[13] Sun Y, Zhang H, Cheng M, et al. New hepatoprotective isoflavone glucosides from Pueraria lobata (Willd.) Ohwi. Nat Prod Res. 2019;33:3485–3492.
[14] Jiang K, Chen H, Tang K, et al. Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncol Lett. 2018;15:167–174.
[15] Li D, Park SH, Shim JH, et al. In vitro enzymatic modification of puerarin to puerarin glycosides by maltnogenic amylase. Carbohydr Res. 2004;339:2789–2797.
[16] Wenjun H, Jing W, Tao L, et al. The protective effect of puerarin on Myocardial Infarction Reperfusion Injury (MIRI): a meta-analysis of randomized studies in rat models. Med Sci Monit. 2015;21:1700–1706.
[17] Zhang H, Liu Y, Lao M, et al. Puerarin protects Alzheimer’s disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol. 2011;46:30–37.
[18] Wei HY, Zhang YJ, Zhao SZ. Puerarin regulates neovascular glaucoma through pigment epithelium-derived growth factor-induced NF-kB signaling pathway. Mol Med Rep. 2018;17:7866–7874.
[19] Wang Z, Liu A, Zhang H, et al. Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles. Graefes Arch Clin Exp Ophthalmol. 2020;258:2407–2418.
[20] Dong H, Wang M, Li Q. Exosomal miR-4488 and miR-1273g-5p inhibit the epithelial-mesenchymal transition of transforming growth factor β2-mediated retinal pigment epithelial cells by targeting ATP-binding cassette A4. Bioengineered. 2021;12:9693–9706.
[21] Xi X, Hu Z, Wu Q, et al. High expression of small nucleolar RNA host gene 3 predicts poor prognosis and promotes bone metastasis in prostate cancer by activating transforming growth factor-beta signaling. Bioengineered. 2022;13:1895–1907.
[22] Pan J, Zhao L. Long non-coding RNA histone deacetylase 4 antisense RNA 1 (HDAC4-AS1) inhibits HDAC4 expression in human ARPE-19 cells with hypoxic stress. Bioengineered. 2021;12:2228–2237.
[23] Hollborn M, Chen R, Wiedemann P, et al. Cytotoxic effects of curcumin in human retinal pigment epithelial cells. PloS one. 2013;8:e59603.
[24] Aung-Htut MT, McIntosh CS, West KA, et al. Vitro validation of phosphorodiamidate morpholino oligomers. molecules. Basel Switzerland. 2019. 24
[25] Lu SM, Grinstein S, Fairn GD. Quantitative live-cell fluorescence microscopy during phagocytosis. Methods Mol Biol. 2017;1519:79–91.
[26] Habtemariam S. Molecular pharmacology of rosmarinic and salvianolic acids: potential seeds for alzheimer’s and vascular dementia drugs. Int J Mol Sci. 2018;19:458.
[27] Li X, Cai Y, Wang YS, et al. Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cells. PloS one. 2012;7:e47600.
You T, Bi Y, Li J, et al. IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling. Sci Rep. 2017;7:41779.

Huang P, Du SX. Puerarin enhances the anti-tumor effect of cisplatin on drug-resistant A549 cancer in vivo and in vitro through activation of the wnt signaling pathway. Cancer Manag Res. 2020;12:6279–6289.

Jeon YD, Lee JH, Lee YM, et al. Puerarin inhibits inflammation and oxidative stress in dextran sulfate sodium-induced colitis mice model. Biomed Pharmacol. 2020;124:109847.

Zhang L, Ge W, Hu K, et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radio-response to human lung adenocarcinoma cancer cells. Mol Biol Rep. 2012;39:89–95.

Lin M, Hu Y, Chen Y, et al. Impacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization. Invest Ophthalmol Vis Sci. 2012;53:6197–6206.

Kurihara T, Westenskow PD, Bravo S, et al. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012;122:4213–4217.

Samardzija M, Barben M, Todorova V, et al. Hif1a and Hif2a can be safely inactivated in cone photoreceptors. Sci Rep. 2019;9:16121.

Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition. Cells. 2020;9:217.

André H, Tunik S, Aronsson M, et al. Hypoxia-Inducible factor-1α is associated with sprouting angiogenesis in the murine laser-induced choroidal neovascularization model. Invest Ophthalmol Vis Sci. 2015;56:6591–6604.

Rosen R, Vagaggini T, Chen Y, et al. Zeaxanthin inhibits hypoxia-induced VEGF secretion by RPE cells through decreased protein levels of hypoxia-inducible factors-1α. Biomed Res Int. 2015;2015:687386.

Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24:5552–5560.

Cui Y, Y-y L, Li J, et al. STAT3 regulates hypoxia-induced epithelial mesenchymal transition in oesophageal squamous cell cancer. Oncol Rep. 2016;36:108–116.

Liu P, Atkinson SJ, Akbareian SE, et al. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci Rep. 2017;7:1–11.